{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:54Z","timestamp":1740144174692,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/148\/01"],"award-info":[{"award-number":["14\/148\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40273-016-0418-8","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T07:49:24Z","timestamp":1465372164000},"page":"981-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence"],"prefix":"10.1007","volume":"34","author":[{"given":"Alexis","family":"Llewellyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"418_CR1","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013."},{"key":"418_CR2","volume-title":"Daclatasvir for treating chronic hepatitis C","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Daclatasvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"key":"418_CR3","unstructured":"World Health Organization. Hepatitis C. Fact sheet N 164; 2015."},{"key":"418_CR4","volume-title":"Hepatitis C in the UK: 2015 report","author":"Public Health England","year":"2015","unstructured":"Public Health England. Hepatitis C in the UK: 2015 report. London: Public Health England; 2015."},{"issue":"2","key":"418_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420. doi: 10.1016\/j.jhep.2013.11.003 .","journal-title":"J Hepatol"},{"issue":"1","key":"418_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48(1):148\u201362. doi: 10.1016\/j.jhep.2007.07.033 .","journal-title":"J Hepatol"},{"issue":"S1","key":"418_CR7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1002\/hep.1840360706","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(S1):S35\u201346. doi: 10.1002\/hep.1840360706 .","journal-title":"Hepatology"},{"key":"418_CR8","unstructured":"National Institute for Health and Care Excellence. Hepatitis C. 2015. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-cgwave0666 . Accessed 30 Nov 2015."},{"key":"418_CR9","unstructured":"National Institute for Health and Care Excellence. Evaluation report for telaprevir for hepatitis C (chronic) [TA252]. 2012. http:\/\/www.nice.org.uk\/guidance\/TA252 Accessed 12 Jan 2015."},{"key":"418_CR10","unstructured":"National Institute for Health and Care Excellence. Evaluation report for boceprevir for hepatitis C (chronic) [TA253]. 2012. http:\/\/www.nice.org.uk\/guidance\/ta253\/documents Accessed 12 Jan 2015."},{"key":"418_CR11","unstructured":"National Institute for Health and Care Excellence. Technology Appraisal 200. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010. http:\/\/www.nice.org.uk\/guidance\/TA200 . Accessed 12 Jan 2015."},{"key":"418_CR12","unstructured":"National Institute for Health and Care Excellence. Evaluation report for simeprevir for hepatitis C (chronic) [ID668]. 2014. http:\/\/www.nice.org.uk\/guidance\/gid-tag455\/documents\/hepatitis-c-chronic-simeprevir-id668-evaluation-report2 . Accessed 12 Jan 2015."},{"key":"418_CR13","unstructured":"National Institute for Health and Care Excellence. Evaluation report for sofosbuvir for hepatitis C (chronic) [ID654]. 2014. http:\/\/www.nice.org.uk\/guidance\/gid-tag445\/documents\/hepatitis-c-chronic-sofosbuvir-evaluation-report2 . Accessed 12 Jan 2015."},{"key":"418_CR14","volume-title":"Ledipasvir\u2013sofosbuvir for treating chronic hepatitis C","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Ledipasvir\u2013sofosbuvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"key":"418_CR15","volume-title":"Ombitasvir\u2013paritaprevir\u2013ritonavir with or without dasabuvir for treating chronic hepatitis C","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Ombitasvir\u2013paritaprevir\u2013ritonavir with or without dasabuvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"key":"418_CR16","unstructured":"Bristol-Myers Squibb Pharmaceuticals Ltd. Summary of Product Characteristics. Daklinza\u00ae 30\u00a0mg and 60\u00a0mg film-coated tablets. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/29129 . Accessed 3rd Feb 2015."},{"issue":"3","key":"418_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321. doi: 10.1056\/NEJMoa1306218 .","journal-title":"N Engl J Med"},{"issue":"4","key":"418_CR18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127\u201335.","journal-title":"Hepatology"},{"key":"418_CR19","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2985","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015. doi: 10.3851\/IMP2985 .","journal-title":"Antivir Ther"},{"issue":"6","key":"418_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","volume":"64","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64(6):948\u201356. doi: 10.1136\/gutjnl-2014-307498 .","journal-title":"Gut"},{"volume-title":"Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies. Hepatology","year":"2014","key":"418_CR21","unstructured":"Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, et al., editors. Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies. Hepatology. Hoboken: Wiley; 2014."},{"key":"418_CR22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652\u20137.","journal-title":"J Hepatol"},{"key":"418_CR23","volume-title":"Sofosbuvir for treating chronic hepatitis C","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Sofosbuvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"key":"418_CR24","volume-title":"Appraisal consultation document","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Appraisal consultation document. Daclatasvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"key":"418_CR25","volume-title":"NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data","author":"R Faria","year":"2015","unstructured":"Faria R, Hernandez Alava M, Manca A, Wailoo AJ. NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data. Sheffield: NICE Decision Support Unit; 2015."},{"issue":"7","key":"418_CR26","doi-asserted-by":"crossref","first-page":"A576","DOI":"10.1016\/j.jval.2014.08.1943","volume":"17","author":"S Batson","year":"2014","unstructured":"Batson S, Mitchell S, King D. The use and acceptance of novel statistical analyses to support technology submissions to hta authorities. Value Health. 2014;17(7):A576\u20137.","journal-title":"Value Health."},{"key":"418_CR27","volume-title":"Final appraisal determination\u2014daclatasvir for treating chronic hepatitis C","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination\u2014daclatasvir for treating chronic hepatitis C. London: National Institute for Health and Care Excellence; 2015."},{"issue":"5","key":"418_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40273-015-0369-5","volume":"34","author":"B Woods","year":"2015","unstructured":"Woods B, Faria R, Griffin S. Assessing the value of new treatments for hepatitis C: are international decision makers getting this right? PharmacoEconomics. 2015;34(5):427\u201333. doi: 10.1007\/s40273-015-0369-5 .","journal-title":"PharmacoEconomics."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:57:30Z","timestamp":1498305450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0418-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}